Document:

Document

Exhibit 10.1

Deciphera Pharmaceuticals, Inc.
Amended and Restated Non-Employee Director Compensation Policy
The purpose of this Amended and Restated Non-Employee Director Compensation Policy (this “Policy”) of Deciphera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company to become members of the Company’s Board of Directors (the “Board”). In furtherance of this purpose, effective as of March 24, 2020 (the “Effective Date”), all non-employee directors of the Board shall be paid compensation for services provided to the Company as set forth below:
Cash Retainers
Annual Retainer for Board Membership:  $50,000 for general availability and participation in meetings and conference calls of our Board (the “Annual Board Retainer”). No additional compensation for attending individual Board meetings.
Additional Annual Retainer for Non-Executive Chairperson of the Board:    $30,000
Additional Annual Retainers for Committee Membership:
						
	Audit Committee Chairperson:	$15,000
	Audit Committee member:	$7,500
		
	Compensation Committee Chairperson:	$10,000
	Compensation Committee member:	$5,000
		
	Nominating and Corporate Governance Committee Chairperson:	$7,500
	Nominating and Corporate Governance Committee member:	$3,750
		
	Science Committee Chairperson:	$10,000
	Science Committee member: 	$5,000

No additional compensation for attending individual committee meetings.                                                                                                          
All cash retainers will be paid quarterly, in arrears, or upon the earlier resignation or removal of the non-employee director. Cash retainers owing to non-employee directors shall be annualized, meaning that non-employee directors who join the Board during the calendar year, such amounts shall be pro-rated based on the number of calendar days served by such director. 
In lieu of receiving cash for her or his Annual Board Retainer, each non-employee director may elect to receive all (but not a portion) of her or his Annual Board Retainer in the form of an equity award of a stock option to purchase that number of shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) with a grant date fair value (based on the Black-Scholes option-pricing model), determined in accordance with the reasonable assumptions and methodologies employed by the Company for calculating the fair value of options under ASC 718. Any such election shall be made (i) for any continuing non-employee director, during the month of December that is before the start of the calendar year with respect to any cash compensation for such calendar year and (ii) for any new non-employee director, within 30 days of her or his election to the Board of Directors; provided that, with respect to 

Exhibit 10.1

calendar year 2020, non-employee directors of the Board as of the Effective Date may make any such election within 30 days following the Effective Date for the portion of the Annual Board Retainer to be earned in 2020 on or following July 1, 2020. Any election (A) shall be irrevocable with respect to such calendar year and (B) shall automatically apply to the Annual Board Retainer for each subsequent calendar year unless otherwise revoked prior to the start of such calendar year. Each such stock option shall be granted effective January 15 of the applicable year (or July 15, in the case of 2020) (noting that if any such date is not a trading day, the next trading day shall be the grant date) and shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the non-employee director’s continued board service through such date (other than the stock options granted in 2020, which shall vest in two equal installments as of the last day of each remaining calendar quarter of 2020).  
All of the foregoing option grants will have an exercise price equal to the fair market value of a share of Common Stock on the date of grant. 
Equity Retainers
Initial Equity Grant: One-time option grant to each new non-employee director upon his/her election to the Board after the Effective Date to purchase shares of Common Stock in such amount and on such terms as authorized by the Board, or by a committee appointed by the Board. 
On the date of each Annual Meeting of Stockholders:  Annual option grant to each non-employee director serving on the Board immediately following the Company’s annual meeting of stockholders to purchase shares of Common Stock in such amount and on such terms as authorized by the Board, or by a committee appointed by the Board.   
All of the foregoing option grants will have an exercise price equal to the fair market value of a share of Common Stock on the date of grant. 
Expenses
The Company shall reimburse all reasonable out-of-pocket expenses incurred by non-employee directors in attending Board and committee meetings.
AMENDED AND RESTATED: March 24, 2020Document

Exhibit 10.2

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED.

This letter agreement (this “Letter Agreement”) is made as of January 17th, 2020 (the “Effective Date”), by and between Deciphera Pharmaceuticals, LLC a limited liability company organized and existing under the laws of Delaware, U.S.A., located at 200 Smith Street, Waltham, MA 02451, U.S.A., (“Deciphera”), and Zai Lab (Shanghai) Co., Ltd., an exempted company organized and existing under the laws of P.R. of China, located at 4F, Bldg 1, Jinchuang Plaza, 4560 Jinke Rd, Shanghai, China, 201210 (“Zai”) in connection with that certain License Agreement entered by and between Deciphera and Zai, dated as of June 10, 2019 (the “License Agreement”).  Capitalized terms used herein and not otherwise defined shall have the meanings given to them in the License Agreement.  The purpose of this Letter Agreement is to clarify several operational matters contemplated by the License Agreement. In connection therewith, the undersigned hereby agrees and acknowledges as follows:
1.[***]
2.For clarity, for Article 6 (Regulatory), Section 13.1(e) (By Zai) and Section 15.8 (Effect of Termination) of the License Agreement, the definition of “Regulatory Approval” shall be amended to mean,
“with respect to a Licensed Product in a region or a country, each approval from the necessary Governmental Authority or Regulatory Authority necessary to conduct Clinical Trials, import, market or sell such Licensed Product in such region, including pricing approvals (but excluding reimbursement approvals).”
3.[***]
4.[***]
5.[***] 
6.Zai shall comply, and shall cause its Affiliates, Sublicensees and subcontractors to comply, with all Applicable Laws, including without limitation GCP and regulations promulgated by the NMPA, in their conduct of all Clinical Trials in the Territory. 
7.Notwithstanding anything to the contrary in Section 6.4 (Adverse Event Reporting) of the License Agreement, Zai shall be responsible for complying with all Applicable Laws governing Adverse Events in the Territory for all Clinical Trials conducted in the Territory and the Parties shall execute a Pharmacovigilance Agreement per the License Agreement to reflect the agreement among the Parties with respect to such matters, including that Zai will provide in English adverse events from Regional Studies for inclusion in a reporting system chosen by Deciphera.
8.Prior to Zai initiating any Clinical Trial in the Territory, Zai (a) shall have and maintain such type and amounts of clinical trial insurance covering the conduct of each such Clinical Trial in the Territory that is normal and customary in the pharmaceutical industry generally for similarly situated companies to conduct each such Clinical Trial; and (b) 

Exhibit 10.2

shall name Deciphera and all its Affiliates as full named insureds thereunder who are each entitled to the full benefits of such insurance policy.  
9.[***]
10.The governing law and dispute resolution provisions of the License Agreement, as amended from time to time, shall apply to the provisions of this letter agreement.  Any notices or other communication required to be provided under the provisions of this Letter Agreement shall be provided in accordance with the notice provision of the License Agreement as amended from time to time.  In the event of a conflict between a term or condition of this Letter Agreement and a term or condition of the License Agreement, the term or condition of this Letter Agreement shall control.  This Letter Agreement may be executed in multiple counterparts which, taken together, shall constitute one and the same agreement.  This Letter Agreement may only be amended with the written consent of both Parties hereto.

[Remainder of Page Intentionally Left Blank]

Exhibit 10.2

IN WITNESS WHEREOF, the Parties intending to be bound have caused this Letter Agreement to be executed by their duly authorized representatives as of the Effective Date.
						
	Deciphera Pharmaceuticals, LLC	Zai Lab (Shanghai) Co., Ltd.
		
	By: /s/ Steve Hoerter	By: /s/ Samantha Du
		
	Name: Steve Hoerter	Name: Samantha Du
		
	Title: President and Chief Executive Officer	Title: Chairman and Chief Executive Officer
		
	Date: 17th, Jan., 2020
	Date: 17th, Jan., 2020Exhibit

Exhibit 4.1

FIFTH SUPPLEMENTAL INDENTURE TO THE INDENTURES 
FIFTH SUPPLEMENTAL INDENTURE (this “Fifth Supplemental Indenture”), dated as of January 22, 2020, among YRL Associates, L.P., a New York limited partnership (“YRL”) and MGP Yonkers Realty Sub, LLC, a New York limited liability company (“MGP Yonkers” and, together with YRL, the “Guaranteeing Entities”), MGP Finance Co-Issuer, Inc., a Delaware corporation (the “Co-Issuer”), MGM Growth Properties Operating Partnership LP, a Delaware limited partnership (the “Issuer” and, together with the Co-Issuer, the “Issuers”), the other Subsidiary Guarantors (as defined in the Indenture referred to herein) and U.S. Bank National Association, as Trustee under the Indenture referred to below (the “Trustee”).
W I T N E S S E T H
WHEREAS, the Issuers have heretofore executed and delivered to the Trustee (i) an indenture, dated as of April 20, 2016 providing for the issuance of 5.625% Senior Notes due 2024 (the “2024 Notes”); (ii) an indenture, dated as of August 12, 2016 providing for the issuance of 4.500% Senior Notes due 2026 (the “2026 Notes”); (iii) an indenture, dated as of September 21, 2017 providing for the issuance of 4.500% Senior Notes due 2028 (the “2028 Notes”); and (iv) an indenture, dated as of January 25, 2019 providing for the issuance of 5.750% Senior Notes due 2027 (the “2027 Notes,” and, collectively, with the 2024 Notes, the 2026 Notes and the 2028 Notes, the “Notes,” and each of (i), (ii), (iii) and (iv) as amended and supplemented, as applicable, by the First Supplemental Indenture dated April 25, 2016, by the Supplemental Indenture dated June 15, 2018, by the Second Supplemental Indenture dated July 10, 2018, by the Third Supplemental Indenture dated January 29, 2019 and by the Fourth Supplemental Indenture dated March 29, 2019 collectively, the “Indentures”);
WHEREAS, the Indentures provide that under certain circumstances the Guaranteeing Entities shall execute and deliver to the Trustee a supplemental indenture pursuant to which the Guaranteeing Entities shall unconditionally guarantee all of the Issuers’ obligations under the Notes and the Indentures on the terms and conditions set forth herein (the “Note Guarantee”); and
WHEREAS, pursuant to Section 9.01 of the Indentures, the Trustee is authorized to execute and deliver this Fifth Supplemental Indenture.
NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Guaranteeing Entities and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows:
1. CAPITALIZED TERMS. Capitalized terms used herein without definition shall have the meanings assigned to them in the Indentures.
2. AGREEMENT TO GUARANTEE. The Guaranteeing Entities hereby agree to provide an unconditional Guarantee on the terms and subject to the conditions set forth in each Note Guarantee and in the Indentures including but not limited to Article 10 thereof.
3. NO RECOURSE AGAINST OTHERS. No director, officer, employee, incorporator or stockholder of the Issuers or any Subsidiary Guarantor, as such, will have any liability for any obligations of the Company or any Subsidiary Guarantors under the Notes, the Indentures, the Note Guarantees or for any claim based on, in respect of, or by reason of, such obligations or their creation. Each Holder of Notes by accepting a Note waives and releases all such liability. The waiver and release are part of the consideration for issuance of the Notes. The waiver may not be effective to waive liabilities under the federal securities laws.
4. NEW YORK LAW TO GOVERN. THE INTERNAL LAW OF THE STATE OF NEW YORK SHALL GOVERN AND BE USED TO CONSTRUE THIS FIFTH SUPPLEMENTAL INDENTURE WITHOUT GIVING EFFECT TO APPLICABLE PRINCIPLES OF CONFLICTS OF LAW TO THE EXTENT THAT THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION WOULD BE REQUIRED THEREBY.

41086.01500

5. COUNTERPARTS. The parties may sign any number of copies of this Fifth Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement.
 
6. EFFECT OF HEADINGS. The Section headings herein are for convenience only and shall not affect the construction hereof.
7. THE TRUSTEE. The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Fifth Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Guaranteeing Entities and the Company.
[Signatures on following page]

IN WITNESS WHEREOF, the parties hereto have caused this Fifth Supplemental Indenture to be duly executed and attested, all as of the date first above written.
Dated: January 22, 2019
	
				
	Guaranteeing Entities:

	 
	 
	 

	

MGP YONKERS REALTY SUB, LLC

	 
	 

	By:
	 
	   /s/ Andrew Hagopian III

	 
	 
	Name:   Andrew Hagopian III

	 
	 
	Title:   Secretary

	 
	 
	 

	YRL ASSOCIATES, L.P.

	By:
	MGP Lessor, LLC

	Its:
	General Partner

	 
	 

	By:
	 
	   /s/ Andrew Hagopian III

	 
	 
	Name:   Andrew Hagopian III
Title:   Secretary

	 

	Issuers:

	MGM GROWTH PROPERTIES OPERATING PARTNERSHIP LP

	 
	 

	By:
	 
	   /s/ Andrew Hagopian III

	 
	 
	Name:   Andrew Hagopian III

	 
	 
	Title:   Assistant Secretary

	 

	MGP FINANCE CO-ISSUER, INC.

	 
	 

	By:
	 
	   /s/ Andrew Hagopian III

	 
	 
	Name:   Andrew Hagopian III

	 
	 
	Title:   Secretary

	 

	
			
	 

	Subsidiary Guarantors:

	MGP LESSOR HOLDINGS, LLC

	 
	 

	By:
	 
	   /s/ Andrew Hagopian III

	 
	 
	Name:   Andrew Hagopian III

	 
	 
	Title:   Secretary

	 

	MGP LESSOR, LLC

	 
	 

	By:
	 
	     /s/ Andrew Hagopian III

	 
	 
	Name:   Andrew Hagopian III

	 
	 
	Title:   Secretary

	 

	
			
	Trustee:

	U.S. BANK NATIONAL ASSOCIATION

	as Trustee

	 
	 

	By:
	 
	/s/ Joshua A. Hahn

	 
	 
	Authorized Signatory

4835-5221-1121v3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}]]